Search

Pimavanserin

Therefore, pimavanserin can be used to treat psychotic symptoms without causing extrapyramidal or worsening motor symptoms. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized

Torasemide

Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.

Amiloride

Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)

Icotinib

growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to

Potassium bicarbonate

Potassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid. It is registered...

Revumenib

[A264688] Aberrant KMT2A is associated with the upregulation of leukemogenic transcription pathways, notably those involving _HOXA_ genes and their co-factor _MEIS1_. … It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.

Methylthioninium

Opicapone

Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase … [L2336] Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations.

Idursulfase

The enzyme activity of idursulfase is dependent on the post-translational modification of a specific cysteine to formylglycine.

Fedratinib

Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.